Porton Advanced News and Resources

Porton Advanced has announced a partnership with TongEYE Medical Technology to support the development of an induced pluripotent stem cell (iPSC)-derived retinal pigment epithelium cell (RPEC) therapy targeting blinding eye diseases such as age-related macular degeneration (AMD). The agreement will see

Porton Advanced, a contract development and manufacturing organisation (CDMO) specialising in advanced therapy medicinal products (ATMPs), has announced a partnership with Hualong Biological to accelerate the development of a novel cell therapy for solid tumours. The agreement covers end-to-end CDMO

Porton Advanced has been appointed the exclusive contract development and manufacturing organisation (CDMO) for Tasly Pharmaceutical Co., Ltd’s dual-targeting CAR-T therapy, P134 Cell Injection. The therapy recently received Investigational New Drug (IND) approval from China’s National Medical Products Administration (Approval No.: 2025LP01030) and

Porton Advanced, a contract development and manufacturing organisation (CDMO) specialising in advanced therapy medicinal products (ATMPs), has announced a partnership with Eureka Therapeutics, a clinical-stage biotechnology company focused on novel T-cell therapies for solid tumours and blood cancers. The collaboration aims

Porton Advanced Solutions has announced a strategic cooperation with Guangzhou Geneseed Biotech Co., Ltd to enhance the development of circRNA-based therapies. The agreement, effective from July 29, 2024, combines Porton Advanced’s end-to-end cell and gene therapy CDMO services with Geneseed

Porton Advanced has strengthened its position in the cell therapy market by introducing the MaxCyte cGMP-grade ExPERT GTx Flow Electroporation instrument to its platform in China. This marks a significant advancement as Porton Advanced becomes the first cell therapy Contract